News | April 17, 2024

CPR-Therapeutics, Inc. Names Mike Black as Chief Strategy Officer

Mike Black

Mike Black


April 17, 2024 —CPR Therapeutics, Inc. (CPR-T), an early-stage medtech startup funded by the N.I.H and N.S.F to develop the next generation technology for cardiopulmonary resuscitation, announced today that Mike Black will be advising the Company as its first Chief Strategy Officer.

CPR Therapeutics, Inc. is developing multimodal cardiopulmonary resuscitation (CPR), a more effective form of automated mechanical CPR. Sudden cardiac arrest is one of the leading causes of sudden death worldwide and there are currently no devices more effective than manual chest compressions. Intact survival after cardiac arrest is below 10% in most communities.

Dave Gaddy, CPR Therapeutic’s CEO said “We could not be more excited to have Mike’s expertise. His background in leading the development of innovative resuscitation and EMS medical devices is uniquely strong. He was CEO of Advanced Circulatory Systems Inc. (ACSI), one of the few start-ups to innovate significantly in CPR. He went on to be Vice President of Global Customer Experience at ZOLL Medical, a leading strategic company in EMS that acquired ACSI in 2015.”

Asked to share his perspective on CPR-T, Mike responded “I’m looking forward to advising the CPR Therapeutics team on the development of this important suite of medical technologies. I have a long-term commitment to improving the outcome of patients suffering cardiac arrest. CPR-T’s approach is a major opportunity to advance care and have a meaningful impact on one of the leading killers worldwide.”

Dr. Paradis, CPR-T’s Founder and Chief Medical Officer added: “Mike is a great fit for helping our start-up company take on one of medicine’s most intractable problems – improving the efficacy of CPR. I genuinely believe our chances for success go up significantly having Mike in this important role.”

For more information: www.cprtherapeutics.com


Related Content

News | Cardiovascular Clinical Studies

April 9, 2026 — Mount Sinai researchers have created an analytic tool using machine learning that can predict ...

Home April 14, 2026
Home
News | Cardiovascular Clinical Studies

April 13, 2026 —The American Heart Association (AHA) has granted Case Western Reserve University the Rapid Impact ...

Home April 13, 2026
Home
News | Cardiovascular Clinical Studies

April 2, 2026 — Iterative Health and US Heart & Vascular (USHV) have announced a strategic partnership to advance ...

Home April 02, 2026
Home
News | Cardiovascular Clinical Studies

March 4, 2026 — UltraSight, a provider of AI-guided cardiac imaging workflows, has announced Late-Breaking clinical ...

Home March 04, 2026
Home
News | Cardiovascular Clinical Studies

Feb. 9, 2026 — HTA and MedAxiom have opened applications for the 2026 HeartX program, a cardiovascular-focused ...

Home February 18, 2026
Home
News | Cardiovascular Clinical Studies

Jan. 5, 2026 — Medera Inc., a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by ...

Home January 05, 2026
Home
News | Cardiovascular Clinical Studies

Nov. 10, 2025 —Genomics, a science-led techbio company, has today announced new research that suggests polygenic risk ...

Home November 12, 2025
Home
News | Cardiovascular Clinical Studies

Oct. 21, 2025 – AskBio Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG ...

Home October 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 25, 2025 — Merck, known as MSD outside of the United States and Canada, has announced that new clinical trial and ...

Home August 25, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 18, 2025 — (Newswise) It’s often mistaken for a heart attack, but Takotsubo cardiomyopathy — previously known as ...

Home August 21, 2025
Home
Subscribe Now